Participants receive secukinumab or a placebo through subcutaneous injection. The dosage is 150 mg per 1 mL solution, administered using a pre-filled syringe.

The goal is to achieve remission of non-radiographic axial spondyloarthritis, a condition characterized by inflammation of the spine and sacroiliac joints.

Participants are assessed to determine if they have achieved remission. Remission is defined by the absence of significant symptoms and inflammation.

This evaluation is crucial to decide if participants can proceed to the next phase of the trial.

Participants who achieve remission enter a double-blind, placebo-controlled phase. This means neither the participants nor the researchers know who receives the active drug or placebo.

The objective is to evaluate if continuous treatment with secukinumab is more effective than placebo in preventing symptom flares.

Participants are monitored for flares, which are episodes of increased disease activity. The primary endpoint is the proportion of participants who remain flare-free at Week 120.

Secondary assessments include the time to flare and the safety and tolerability of the treatment, evaluated through adverse events and changes in laboratory parameters and vital signs.

The trial is estimated to end by June 19, 2030. Participants’ data will contribute to understanding the long-term effectiveness and safety of secukinumab in maintaining remission.